January 2026 in “Springer Link (Chiba Institute of Technology)” Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
January 2026 in “E3S Web of Conferences” Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
November 2025 in “The Journal of Sexual Medicine” Using Mark Cuban Cost Plus Drug Company can save money on men's health medications compared to Medicare.
August 2025 in “International Journal of Dermatology” Saw palmetto is less effective than finasteride and lacks regulation, raising safety and efficacy concerns.
April 2025 in “Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )” Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
December 2024 in “Zanco Journal of Medical Sciences” Finasteride and dutasteride are equally effective and safe for treating BPH.
September 2024 in “LUTS Lower Urinary Tract Symptoms” People with hair loss may have worse urinary symptoms due to an enlarged prostate.
August 2024 in “Australasian Journal of Dermatology” Finasteride users have a very low risk of mental health issues, but those with hair loss may have slightly higher anxiety and depression.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
June 2024 in “Research Square (Research Square)” Finasteride overdose can cause acute pancreatitis.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
April 2024 in “International journal of impotence research” Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.
January 2024 in “Journal of Applied Health Sciences and Medicine” Nephrolepis biserrata may improve fertility and reduce prostate issues in males.
December 2023 in “Bulletin of Pharmaceutical Sciences Assiut” Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
April 2023 in “Jordan Medical Journal” Men with male pattern baldness are more likely to have benign prostatic hyperplasia.
March 2023 in “Enciclopédia Biosfera” Finasteride effectively treats BPH but requires continuous use to maintain benefits.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
September 2021 in “The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy” COVID-19 worsens urinary symptoms in men with benign prostatic hyperplasia, requiring careful treatment management.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
January 2020 in “Journal of Men s Health” The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.